The present disclosure relates to methods and compositions for making bio-based, biodegradable, and non-bioaccumulating lubricating base oils generated by esterifying alkoxylated polyols (average alkoxylation 3) with long-chain (C14) saturated and unsaturated fatty acids (FA) or fatty acids modified using industry recognized techniques.

Calibrants and methods of making the same include using mixtures of multifunctional core compounds or multifunctional dendrimers that are functionalized to yield a set of discrete compounds which cover a range of collisional cross sections (CCSs) for calibrating ion mobility and variation in molecular weight to calibrate the mass to charge (m/z) measurements of mass spectrometry, as well as for calibrating tandem instruments that measure both dimensions. Methods of using the calibrants are also disclosed, such as in mass spectrometry.

Calibrants and methods of making the same include using mixtures of multifunctional core compounds or multifunctional dendrimers that are functionalized to yield a set of discrete compounds which cover a range of collisional cross sections (CCSs) for calibrating ion mobility and variation in molecular weight to calibrate the mass to charge (m/z) measurements of mass spectrometry, as well as for calibrating tandem instruments that measure both dimensions. Methods of using the calibrants are also disclosed, such as in mass spectrometry.

The present invention relates to a process for the preparation of mixed polyol-carboxylic acid esters having a molecular weight of greater than or equal to 200 g/mol and less than or equal to 1000 g/mol, wherein a polyol is reacted in an at least two-step reaction with different monocarboxylic acids in the form of monocarboxylic acids or of monocarboxylic acid anhydrides, wherein the different monocarboxylic acids are reacted with the polyol in the order of their reactivity in the esterification reaction, starting with the lowest reactivity, wherein the monocarboxylic acids with the lower reactivity are reacted at least partly as monocarboxylic acid anhydride and the monocarboxylic acid with the highest reactivity is reacted thereafter as monocarboxylic acid with the polyol. Furthermore, the present invention relates to the use of the process for the preparation of mixed polyol esters.

The present invention relates to a process for the preparation of mixed polyol-carboxylic acid esters having a molecular weight of greater than or equal to 200 g/mol and less than or equal to 1000 g/mol, wherein a polyol is reacted in an at least two-step reaction with different monocarboxylic acids in the form of monocarboxylic acids or of monocarboxylic acid anhydrides, wherein the different monocarboxylic acids are reacted with the polyol in the order of their reactivity in the esterification reaction, starting with the lowest reactivity, wherein the monocarboxylic acids with the lower reactivity are reacted at least partly as monocarboxylic acid anhydride and the monocarboxylic acid with the highest reactivity is reacted thereafter as monocarboxylic acid with the polyol. Furthermore, the present invention relates to the use of the process for the preparation of mixed polyol esters.

Provided in the present invention are ingenol compounds and a use thereof in preparing an anti-HIV latency drug. In particular, provided in the present invention is a use of ingenol compounds and pharmaceutically acceptable salts thereof for preparing a drug for: (a) intervening with HIV viral latency; (b) activating an HIV virus that has been integrated into mammalian genomes; and/or (c) inducing the expression of the dormant HIV provirus in infected cells. The compounds of the present invention may also be used in combination with antiretroviral drugs to accelerate the removal of latent viral reservoirs.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS, or the development of neoplasms in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing Th1 cytokine expression, decreasing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant cells, inducing remission, maintaining remission, as chemotherapeutic agents, as well as for decreasing symptoms of cytopathic diseases and opportunistic infections that may accompany such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols, therapeutic agents used to treat opportunistic infections due to HIV, or chemotherapeutic agents to yield more effective treatment tools against cytopathic diseases in mammalian subjects.

An organic compound, a three-dimensional organic structure formed by using the organic compound, a separation sieve and an optical layer having the organic structure, and an optical device having the optical layer as an optical amplification layer are provided. The organic structure includes a plurality of organic molecules self-assembled by non-covalent bonding. Each of the unit organic molecules has an aromatic ring, a first pair of substituents being connected to immediately adjacent positions of substitutable positions of the aromatic ring, and a second pair of substituents being connected to immediately adjacent positions of remaining substitutable positions of the aromatic ring. The unit organic molecules are self-assembled by van der Waals interaction, London dispersion interaction or hydrogen bonding between the first and the second pairs of the substituents and by pi-pi interactions between the aromatic rings.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.